Insulet Corporation (NASDAQ:PODD) Shares Bought by Achmea Investment Management B.V.

Achmea Investment Management B.V. raised its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 36.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,757 shares of the medical instruments supplier's stock after acquiring an additional 1,808 shares during the period. Achmea Investment Management B.V.'s holdings in Insulet were worth $1,775,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Horizon Investments LLC raised its position in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after purchasing an additional 42 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Insulet by 2.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after buying an additional 48 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Insulet by 5.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after buying an additional 50 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Insulet by 2.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock valued at $566,000 after acquiring an additional 50 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Insulet by 4.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock valued at $285,000 after acquiring an additional 51 shares during the period.

Insider Activity at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the transaction, the senior vice president owned 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.39% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PODD shares. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Wells Fargo & Company set a $322.00 target price on Insulet in a report on Monday, April 28th. Truist Financial initiated coverage on shares of Insulet in a research note on Monday, June 16th. They set a "buy" rating and a $365.00 price target on the stock. Citigroup reissued a "buy" rating and issued a $380.00 price objective (up previously from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Finally, Royal Bank Of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price on the stock. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insulet Stock Up 0.4%

Shares of Insulet stock traded up $1.10 during trading hours on Monday, hitting $314.18. The company had a trading volume of 679,918 shares, compared to its average volume of 713,755. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. The company's 50-day moving average is $297.69 and its two-hundred day moving average is $277.69. The company has a market cap of $22.11 billion, a P/E ratio of 56.51, a price-to-earnings-growth ratio of 2.79 and a beta of 1.37. Insulet Corporation has a twelve month low of $129.55 and a twelve month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The company had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. During the same quarter last year, the company posted $0.73 earnings per share. The business's quarterly revenue was up 28.8% compared to the same quarter last year. Analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.